9.305
                                            Precedente Chiudi:
              $9.73
            Aprire:
              $9.35
            Volume 24 ore:
                6.54M
            Relative Volume:
              1.11
            Capitalizzazione di mercato:
                $726.31M
            Reddito:
              -
            Utile/perdita netta:
              $-209.96M
            Rapporto P/E:
              -2.9446
            EPS:
                -3.16
            Flusso di cassa netto:
                $-176.27M
            1 W Prestazione:
              -0.27%
            1M Prestazione:
              +96.72%
            6M Prestazione:
                -7.04%
            1 anno Prestazione:
              -21.81%
            Replimune Group Inc Stock (REPL) Company Profile
Nome
                  
                      Replimune Group Inc
                    
                Settore
                  Industria
                  Telefono
                  
                      (781) 222-9600
                    
                Indirizzo
                  
                      500 UNICORN PARK, WOBURN, MA
                    
                Confronta REPL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                REPL
                            
                             
                        Replimune Group Inc 
                           | 
                    9.305 | 759.48M | 0 | -209.96M | -176.27M | -3.16 | 
| 
                         
                          
                                VRTX
                            
                             
                        Vertex Pharmaceuticals Inc 
                           | 
                    426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 | 
| 
                         
                          
                                REGN
                            
                             
                        Regeneron Pharmaceuticals Inc 
                           | 
                    642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 | 
| 
                         
                          
                                ALNY
                            
                             
                        Alnylam Pharmaceuticals Inc 
                           | 
                    434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 | 
| 
                         
                          
                                ARGX
                            
                             
                        Argen X Se Adr 
                           | 
                    826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 | 
| 
                         
                          
                                INSM
                            
                             
                        Insmed Inc 
                           | 
                    186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 | 
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione | 
|---|---|---|---|
| 2025-10-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy | 
| 2025-10-20 | Aggiornamento | JP Morgan | Underweight → Neutral | 
| 2025-10-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform | 
| 2025-10-20 | Aggiornamento | Piper Sandler | Neutral → Overweight | 
| 2025-10-20 | Aggiornamento | Wedbush | Neutral → Outperform | 
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight | 
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight | 
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform | 
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight | 
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral | 
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral | 
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform | 
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral | 
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral | 
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight | 
| 2024-08-28 | Iniziato | ROTH MKM | Buy | 
| 2023-04-17 | Ripresa | Piper Sandler | Overweight | 
| 2021-11-19 | Iniziato | Piper Sandler | Overweight | 
| 2021-10-15 | Ripresa | BTIG Research | Buy | 
| 2020-11-17 | Iniziato | BTIG Research | Buy | 
| 2020-11-02 | Iniziato | Jefferies | Buy | 
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy | 
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral | 
| 2020-05-05 | Iniziato | Barclays | Overweight | 
| 2019-09-04 | Iniziato | ROTH Capital | Buy | 
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy | 
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight | 
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy | 
| 2019-04-25 | Iniziato | Wedbush | Outperform | 
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral | 
| 2018-08-14 | Iniziato | JP Morgan | Overweight | 
| 2018-08-14 | Iniziato | Leerink Partners | Outperform | 
                    Mostra tutto
                    
                  
                Replimune Group Inc Borsa (REPL) Ultime notizie
Trend analysis for Replimune Group Inc. this week2025 Historical Comparison & AI Driven Stock Movement Reports - newser.com
What risks investors should watch in Replimune Group Inc. stockM&A Rumor & High Accuracy Swing Trade Signals - newser.com
BMO Capital Upgrades Replimune Group to Market Perform From Underperform, Adjusts Price Target to $11 From $2 - MarketScreener
BMO Capital Upgrades Replimune Group (REPL) - Nasdaq
Smart tools for monitoring Replimune Group Inc.’s price actionJuly 2025 Decliners & Long-Term Growth Plans - newser.com
REPL: Analyst Raises Price Target and Upgrades Rating to Market Perform | REPL Stock News - GuruFocus
Replimune Group Inc. stock volume spike explainedPortfolio Update Report & Fast Momentum Stock Entry Tips - newser.com
Will Replimune Group Inc. stock benefit from AI adoptionRate Hike & Breakout Confirmation Alerts - newser.com
What recovery options are there for Replimune Group Inc.Market Trend Review & Community Verified Watchlist Alerts - newser.com
Price momentum metrics for Replimune Group Inc. explainedMarket Movement Recap & Safe Entry Momentum Tips - newser.com
How Replimune Group Inc. stock compares to growth peersPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Replimune stock rating upgraded by BMO Capital on improved FDA outlook - Investing.com Canada
What hedge fund activity signals for Replimune Group Inc. stockJuly 2025 WrapUp & Daily Volume Surge Trade Alerts - newser.com
How to use Fibonacci retracement on Replimune Group Inc.July 2025 Volume & Daily Stock Trend Watchlist - newser.com
How to build a custom watchlist for Replimune Group Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
What to do if you’re stuck in Replimune Group Inc.Market Sentiment Summary & Daily Price Action Insights - newser.com
Is Replimune Group Inc. stock a buy before product launchesPortfolio Return Report & Community Trade Idea Sharing - newser.com
Why Replimune Group Inc. stock is a must watch in 2025Trade Signal Summary & Daily Profit Maximizing Tips - newser.com
Brokers Set Expectations for Replimune Group Q2 Earnings - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Up 9.2% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Replimune Group Q2 Earnings - MarketBeat
Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq
Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - MarketBeat
How Replimune Group Inc. stock reacts to Fed rate cuts2025 Year in Review & Fast Gaining Stock Reports - Fundação Cultural do Pará
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):